GlassScriptPhysician profile
Michael J Findura
NPI 1922072420
$5,264.89
in general payments reported to CMS, 2019-2025
36 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $378 · 2021: $748 · 2022: $1,239 · 2023: $717 · 2024: $503 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $651.98 | 2020-2025 | Breztri, Airsupra, Fasenra |
| Amgen INC. | $391.73 | 2021-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $352.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $297.86 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $279.36 | 2019-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $261.23 | 2025 | Korlym |
| Pfizer INC. | $191.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $171.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $159.99 | 2022 | |
| Exact Sciences Corporation | $156.66 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.92 | 2020-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $124.33 | 2022-2023 | |
| Lundbeck LLC | $97.71 | 2022-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $97.01 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $91.68 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $89.67 | 2021-2023 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $72.18 | 2024-2025 | NP Thyroid 60 |
| Tolmar, INC. | $70.43 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $67.02 | 2019-2023 | Belsomra, Januvia, Janumet |
| Xeris Pharmaceuticals, INC. | $50.81 | 2022-2025 | Gvoke Hypopen |
| Genentech USA, INC. | $42.60 | 2020-2021 | |
| Ibsa Pharma INC. | $42.55 | 2022-2025 | Licart, Flector, Tirosint |
| Amarin Pharma, INC. | $40.38 | 2019-2021 | |
| Eisai INC. | $40.36 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.78 | 2022 | |
| Currax Pharmaceuticals LLC | $37.98 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $17.40 | 2024 | Tlando |
| Ars Pharmaceuticals Operations, INC. | $15.87 | 2025 | Neffy |
| Biohaven Pharmaceuticals, INC. | $15.49 | 2021 | |
| Aytu Biopharma, INC. | $15.00 | 2020 | |
| Astellas Pharma US INC | $14.95 | 2019 | |
| Sumitomo Pharma America, INC. | $14.30 | 2023 | Gemtesa |
| Halozyme INC | $14.22 | 2023 | |
| Acerus Pharmaceuticals Corporation | $12.93 | 2021 | |
| Clarus Therapeutics INC. | $12.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Findura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.